Safety and immunogenicity of a booster dose of dTPa Vaccine (Boostrix) co-admnd. with Aventis Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra) vs admn. of either vaccine alone in healthy adolescents.

Trial Profile

Safety and immunogenicity of a booster dose of dTPa Vaccine (Boostrix) co-admnd. with Aventis Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra) vs admn. of either vaccine alone in healthy adolescents.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Diphtheria; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Feb 2012 Actual patient number changed from 1341 to 1376 as reported by ClinicalTrials.gov.
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top